# A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

> **NCT06857955** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 380 (estimated)

## Conditions studied

- Hypertension

## Interventions

- **OTHER:** Saline
- **DRUG:** QCZ484

## Key facts

- **NCT ID:** NCT06857955
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-26
- **Primary completion:** 2027-01-29
- **Final completion:** 2028-04-05
- **Target enrollment:** 380 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857955, "A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06857955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*